This SUMMIT basket trial study evaluated the efficacy of neratinib alone or in combination with trastuzumab in patients with HER2-mutant metastatic triple-negative breast cancer (TNBC). Results showed confirmed objective response rates of 40% for neratinib alone and 35.3% for the combination, with median progression-free survival times of 2.89 and 6.24 months, respectively. Circulating tumor DNA (ctDNA) monitoring correlated decreases in HER2 mutation variant allele frequencies with treatment response and identified the emergence of resistance mutations. The neratinib and trastuzumab combination appears to prolong responses compared to neratinib alone, offering a novel approach for biomarker-defined metastatic TNBC.
This retrospective study investigated prognostic factors and outcomes of postmastectomy radiation therapy (PMRT) following neoadjuvant chemotherapy (NAC) and mastectomy for stage II-III breast cancer. It included 178 patients with a median follow-up of 64 months. The findings indicated that response to NAC, molecular subtype, and pathologic stage are independent predictors of treatment outcomes. PMRT did not offer significant benefits for patients with pathologically node-negative disease (ypN0) but significantly improved locoregional control, progression-free survival, and overall survival in those with residual lymph nodes (ypN1-3). Triple-negative subtype and non-response to NAC were identified as poor prognostic factors.
This study identified and functionally validated lipid droplet (LD)-associated prognostic biomarkers in breast cancer through integrative multi-omics and machine learning. A prognostic model, built using the StepCox[both]+plsRcox algorithm, effectively stratified patients across molecular subtypes, outperforming traditional ER/PR/HER2 status. Key genes, SQLE and SOCS3, were identified with opposing roles: SQLE promoting adipogenesis and SOCS3 inhibiting it, influencing the tumor microenvironment and immune infiltration. Modulating these genes suppressed tumor growth and polarized macrophages towards an M1 phenotype, highlighting their potential as therapeutic targets.
Improved survival rates for reproductive-age breast cancer patients highlight significant oncofertility challenges. Fertility preservation, gonadotoxicity, and pregnancy safety are key concerns requiring early and integrated management within the therapeutic plan. Prompt referral for fertility preservation is crucial, ensuring it does not compromise oncologic outcomes. Modern therapies such as PARP inhibitors, CDK4/6 inhibitors, HER2-monoclonal antibodies, and endocrine treatments raise specific questions due to a lack of prospective human fertility data. A precautionary approach is recommended, including effective contraception and adherence to washout periods.
This study evaluates the efficacy of qPCR for HER2 status assessment in invasive ductal carcinoma of the breast, comparing it with IHC and FISH. Results demonstrate high concordance between qPCR and FISH, particularly in resolving equivocal IHC 2+ cases. Furthermore, exploratory genomic profiling via WES on high-risk subtypes (HER2 3+ and TNBC) revealed somatic mutations in key genes such as TP53, BRCA1, and MYCN, as well as AR expression in TNBC. These findings highlight qPCR’s potential as an accurate diagnostic tool and provide a foundation for future precision oncology strategies.